Ironwood Pharmaceuticals, Inc.
IRWD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $351 | $443 | $411 | $414 |
| % Growth | -20.6% | 7.8% | -0.8% | – |
| Cost of Goods Sold | $8 | $6 | $1 | $70 |
| Gross Profit | $344 | $437 | $409 | $343 |
| % Margin | 97.9% | 98.6% | 99.7% | 83% |
| R&D Expenses | $111 | $116 | $44 | $70 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $116 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $139 | $1,266 | -$1 | $41 |
| Operating Expenses | $251 | $1,382 | $159 | $111 |
| Operating Income | $93 | -$945 | $250 | $232 |
| % Margin | 26.5% | -213.5% | 61% | 56.1% |
| Other Income/Exp. Net | -$28 | -$3 | $2 | -$32 |
| Pre-Tax Income | $65 | -$948 | $252 | $201 |
| Tax Expense | $64 | $83 | $77 | -$328 |
| Net Income | $1 | -$1,002 | $175 | $528 |
| % Margin | 0.3% | -226.4% | 42.6% | 127.7% |
| EPS | 0.006 | -6.45 | 1.13 | 3.26 |
| % Growth | 100.1% | -670.8% | -65.3% | – |
| EPS Diluted | 0.006 | -6.45 | 0.96 | 3.21 |
| Weighted Avg Shares Out | 159 | 155 | 154 | 162 |
| Weighted Avg Shares Out Dil | 160 | 155 | 186 | 164 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $19 | $10 | $1 |
| Interest Expense | $33 | $22 | $8 | $31 |
| Depreciation & Amortization | $2 | $2 | $1 | $2 |
| EBITDA | $98 | $197 | $261 | $234 |
| % Margin | 27.8% | 44.6% | 63.7% | 56.5% |